Original Article

You have full text access to this OnlineOpen article

Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma

  1. Donald Poon M.D.1,
  2. Balram Chowbay Ph.D.2,
  3. Yin-Bun Cheung Ph.D.2,
  4. Swan-Swan Leong M.D.1,
  5. Eng-Huat Tan M.D.1,†,*

Article first published online: 20 DEC 2004

DOI: 10.1002/cncr.20802

Issue

Cancer

Cancer

Volume 103, Issue 3, pages 576–581, 1 February 2005

Additional Information

How to Cite

Poon, D., Chowbay, B., Cheung, Y.-B., Leong, S.-S. and Tan, E.-H. (2005), Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer, 103: 576–581. doi: 10.1002/cncr.20802

Author Information

  1. 1

    Department of Medical Oncology, National Cancer Center, Singapore

  2. 2

    Division of Clinical Trials and Epidemiological Sciences, National Cancer Center, Singapore

  1. †

    Fax: (011) 65 62272759

*Department of Medical Oncology, National Cancer Center, Singapore, 11 Hospital Drive, Singapore 169610

Publication History

  1. Issue published online: 20 JAN 2005
  2. Article first published online: 20 DEC 2004
  3. Manuscript Accepted: 14 OCT 2004
  4. Manuscript Revised: 4 OCT 2004
  5. Manuscript Received: 9 AUG 2004

Funded by

  • Aventis Pharma (Singapore)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (86K)

REFERENCES

  • 1
    ParkinDM, WhelanSL, FerleyJ, RaymondL, YoungJ, editors. Cancer Incidence in Five Continents. Volume VII. Lyon: IARC No. 143, 1997.
  • 2
    Chia KS, Seow A, Lee HP, Shanmugaratnam K. Cancer incidence in Singapore, 1993–1997. Singapore: Singapore Cancer Registry, 2000.
  • 3
    Shanmugaratnam K, Sobin LH. Nasopharyngeal carcinoma. In: ShanmugaratnamK, SobinLH, editors. International histological classification of tumours. Geneva: World Health Organization, 1978; 19: 13–15.
  • 4
    Zheng X, Yan L, Nilsson B, Eklund G, Drettner B. Epstein Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. Acta Oncol. 1994; 33: 867–872.
  • 5
    Shanmugaratnam K, Chan SH, de-Thé G, et al. Histopathology of nasopharyngeal carcinoma. Correlations with epidemiology, survival rates and other biological characteristics. Cancer. 1979; 44: 1029–1044.
    Direct Link:
  • 6
    Au E, Ang PT. A Phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 1994; 5: 87–89.
  • 7
    Boussen H, Cvitkovic E, Wendling JL, et al. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fluorouracil. J Clin Oncol. 1991; 9: 1675–1681.
  • 8
    Hasbini A, Mahjoubi R, Fandi A, et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol. 1999; 10: 421–425.
  • 9
    Chi KH, Chan WK, Cooper DL, et al. A Phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil and leucovorin in nasopharyngeal carcinoma. Cancer. 1994; 15: 247–252.
    Direct Link:
  • 10
    Gebbia V, Zerillo G, Restivo G, et al. Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases. Br J Cancer. 1993; 68: 191–194.
  • 11
    Wang TL, Tan YO. Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singapore. 1991; 20: 601–603.
  • 12
    Tay MH, Ong YK, Foo KF, et al. The role of salvage chemotherapy in metastatic nasopharyngeal carcinoma. Proc Am Soc Clin Oncol. 2004; 20: 199b.
  • 13
    Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic nasopharyngeal cancer. Ann Oncol. 1998; 9: 327–329.
  • 14
    Tan EH, Khoo KS, Wee J, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999; 10: 235–237.
  • 15
    Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol. 2002; 13: 150–156.
  • 16
    Zhang Q, Zhou K, Ling G. Apoptosis of nasopharyngeal carcinoma cells induced by topoisomerase I inhibitor [in Chinese]. Zhonghua Er Bi Yan Hou Ke Za Zhi. 1997; 32: 332–335.
  • 17
    Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 1991; 83: 1164–1168.
  • 18
    Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol. 1996; 23(1 Suppl 3 ): 21–26.
  • 19
    Murphy BA, Cmelak A, Burkey B, et al. Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology. 2001; 15(7 Suppl 8 ): 47–52.
  • 20
    World Health Organisation. Handbook for reporting results of cancer treatment. Geneva: World Health Organisation, 1979.
  • 21
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international trials in oncology. J Natl Cancer Inst. 1993; 85: 365–376.
  • 22
    Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual. 3rd edition. Brussels: EORTC, 2001.
  • 23
    Simon RM. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989; 10: 1–10.
  • 24
    Fairclough DL. Design and analysis of quality of life studies in clinical trials. London: Chapman & Hall, 2002: 101–104.
  • 25
    Kanat O, Evrensel T, Manavoglu O, et al. Single-agent irinotecan as second-line treatment for advanced gastric cancer. Tumori. 2000; 89: 405–407.
  • 26
    Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer. 1996; 32A(Suppl 3): S13–S17.
  • 27
    Sanchez R, Esteban E, Palacio I, et al. Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes. Invest New Drugs. 2003; 21: 459–463.
  • 28
    Fukuoka M, Niitani H, Suzuki A, et al. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992; 10: 16–20.
View Full Article (HTML) Get PDF (86K)